Hailing Lu, MD, PhD - Faculty - Division of Medical Oncology - University of Washington

Faculty

Hailing Lu, MD, PhD

Hailing Lu, MD, PhD

Research Assistant Professor
Department of Medicine
Division of Oncology

Mailing Address

Tumor Vaccine Group
815 Mercer Street
Seattle, WA 98109

Admin Contact

N/A

Specialty / Expertise

Breast Cancer

Research Interests

  • Cancer immunotherapy
  • Complementary and alternative medicine (CAM)

Current Research Projects

PSK as neoadjuvant therapy for locally advanced breast cancer Funding source: NIH R01 CA138547 The major goal of this project is to develop PSK, a novel TLR2 agonist extracted from medical mushroom Trametes versicolor, as new therapy for breast cancer patients. Preliminary studies have demonstrated that PSK is a potent and selective TLR2 agonist. It has potent anti-tumor effect via activation of DC, NK, and CD8 T cells. Combining PSK to paclitaxel and HER2 targeted monoclonal Ab therapy has synergistic anti-tumor effect. Our long-term goal is to develop novel therapies that combine CAM to standard therapy.

Training

Dr. Lu received her MD from Sun Yat-sen University of Medical Sciences, Guangzhou, PRC and her PhD from the University of Washington, Seattle, WA. She was a Post-Doctoral Fellow at the Fred Hutchinson Cancer Research Center, Seattle, WA.

Selected Publications

Lu H, Wagner W, Gad E, Yang Y, Duan H, Amon LM, Van Denend N, Larson ER, Chang A, Tufvesson H, Disis ML.  Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010; 184:5360-5367.

Lu H. FOXP3 expression and prognosis: role of both the tumor and T cells. J Clin Oncol 2009; 27: 1735-6.

Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008; 7:1388-94.

Lu H, Goodell V, Disis ML. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets 2007; 11: 235-44

Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor bearing neu transgenic mice predicts human tumor antigens. Cancer Res 2006; 66: 9754-61

Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 2006;177:1526-33

Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 2006;177:84-91

Lu H, Zhao Z, Kalina T, Gillespy T, 3rd, Liggitt D, Andrews RG, Maloney DG, Kiem HP, Storek J. Interleukin-7 improves reconstitution of antiviral CD4 T cells. Clin Immunol 2005;114:30-41

Kalina T*, Lu H*, Zhao Z, Blewett E, Dittmer DP, Randolph-Habecker J, Maloney DG, Andrews RG, Kiem HP, Storek J. De novo generation of CD4 T cells against viruses present in the host during immune reconstitution. Blood 2005;105:2410-4. (*: co-first author)

Last updated: June 2010

Top